The Latest Cardiac and Vascular News
NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Johnson & Johnson1 (NYSE: JNJ) announced today it has successfully completed the acquisition of V-Wave Ltd., a privately-held company focused on developing innovative treatment options for patients with heart failure. V-Wave will operate as part of Johnson & Johnson MedTech. The acquisition of V-Wave extends Johnson & Johnson […]
Results presented at ACC.24 showed that overall neutral results were due to directionally opposite effects in patients with reduced vs. preserved left ventricular ejection fraction Heart failure patients with reduced ejection (HFrEF) had 45% fewer adverse cardiovascular events, whereas…
CAESAREA, Israel, March 28, 2024 /PRNewswire/ — V-Wave today announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo taking place April 6-8 in Atlanta. RELIEVE-HF is a randomized, double-blind, placebo-procedure-controlled, multicenter, multinational, pivotal trial of the V-Wave® Ventura® Interatrial Shunt in symptomatic patients […]
The RELIEVE-HF trial of the Ventura® Shunt System includes patients with reduced and preserved left ventricular function etiologies for heart failure CAESAREA, Israel, Oct. 24, 2022 /PRNewswire/ — V-Wave, announced today the completion of enrollment in RELIEVE-HF, a prospective, randomized, double-blinded, sham-controlled, multi-center pivotal clinical trial. The RELIEVE-HF study is assessing the safety […]
Echo Core Laboratory Data Demonstrates the Potential of a 5-mm Diameter Shunt to Reduce Filling Volumes and Enhance Systolic Function of Both Ventricles, Consistent with Reverse Cardiac Remodeling MADRID, May 23, 2022 /PRNewswire/ — V-Wave Ltd, manufacturer of the V-Wave Ventura investigational interatrial shunt device to help patients with advanced heart failure (HF), […]
Funds Support Completion of Pivotal Clinical Trial of V-Wave Implantable Interatrial Cardiac Shunt for Heart Failure CAESAREA, Israel and AGOURA, Calif., Dec. 16, 2021 /PRNewswire/ — V-Wave Ltd., a cardiovascular device company developing proprietary, minimally invasive interatrial shunt devices for treating patients with severe symptomatic heart failure (HF) and pulmonary arterial hypertension (PAH), announced […]
Seasoned Medical Device Executive Joins Breakthrough Structural Heart Company CAESAREA, Israel and AGOURA HILLS, Calif., Dec. 2, 2020 /PRNewswire/ — V-Wave Ltd., a cardiovascular device company developing proprietary, minimally invasive interatrial shunt devices for treating patients with severe symptomatic heart failure (HF) and pulmonary arterial hypertension (PAH), announced the appointment of Bill Hughes as its Chief Financial […]
Funds Support Further Development of V-Wave Implantable Interatrial Cardiac Shunt for Heart Failure and Pulmonary Hypertension CAESAREA, Israel and AGOURA HILLS, Calif., Sept. 22, 2020 /PRNewswire/ — V-Wave Ltd., a cardiovascular device company developing proprietary, minimally invasive interatrial shunt devices for treating patients with severe symptomatic heart failure (HF) and pulmonary arterial hypertension (PAH), announced […]
CAESAREA, Israel and AGOURA HILLS, Calif., March 5, 2020 /PRNewswire/ — V-Wave Ltd., a privately held medical device company developing novel implantable devices for the treatment of Heart Failure (HF), today announced that its Ventura™ Interatrial Shunt System received CE Mark and is now approved to be marketed for use in the European Union. “More than 26 […]
CAESAREA, Israel, Sept. 12, 2019 /PRNewswire/ — V-Wave Ltd., a privately held medical device company developing novel implantable interatrial shunt devices, today announced that the U.S. Food and Drug Administration (FDA) has granted the company a second Breakthrough Device Designation – the first was for its interatrial shunt for Heart Failure (HF), and […]
